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ABSTRACT 
Objective: The purpose of this study was to enhance the dissolution pattern of the practically water-insoluble diuretic drug, furosemide through its 
formulation into liquisolid tablets.  
Methods: A mathematical model was used to formulate four liquisolid powder systems using polyethylene glycol 400 as a non-volatile water 
miscible liquid vehicle. The liquid loading factors of the vehicle were used to calculate the optimum quantities of carrier (Avicel PH 102) and coating 
materials (Aerosil 200) needed to prepare acceptably flowing and compactible powder mixtures and (R) ratio used was 25. The liquisolid tablets 
were evaluated for weight variation, percent friability, hardness, content uniformity, disintegration time and in vitro drug release profile. Drug and 
the prepared systems were characterized by fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and powder x-
ray diffraction (PXRD) studies.  
Results: The enhanced dissolution rate due to the increased wetting properties and the large available surface areas for dissolution were obtained 
in case of the liquisolid tablets. The selected optimal formulation (F2) of 50% drug concentration released 90% of its content during the first 10 min 
compared to 65% of DCT. FTIR studies revealed that there was no interaction between drug and polymers. DSC and PXRD indicated conversion of 
crystalline to amorphous form of furosemide.  
Conclusion: The dissolution rate of furosemide can be enhanced to a great extent by liquisolid technique. 
Keywords: Furosemide, Liquisolid compact, PEG 400, Co-processed super disintegrant, Solvent evaporation method 




The poor dissolution rate of water-insoluble drugs confronts a major 
obstacle in the development of pharmaceutical dosage forms. The 
drugs which are poorly water soluble will be released at a slow rate 
owing to their limited solubility within gastrointestinal tract [1]. In 
general drugs with low aqueous solubility (lower than100µg/ml) 
show dissolution-limited and incomplete absorption from the 
gastrointestinal tract of animals and humans [2]. 
The various properties of drug-like solubility, particle size, 
polymorphism, salt form, complexation, wettability affect drug 
dissolution and its rate and can be targeted to enhance dissolution of 
poorly water-soluble drugs [3]. Some commonly used physical 
modifications to enhance the dissolution of API includes: (a) 
Reducing particle size to increase surface area, thus increasing 
dissolution rate of drug, (b) solubilization in surfactant systems, (c) 
formation of water-soluble complexes, (d) drug derivatization such 
as a strong electrolyte salt form that usually has higher dissolution 
rate, and (e) manipulation of solid state of drug substance to 
improve drug dissolution, i.e., by decreasing crystallinity of drug 
substance through formation of solid solutions [4]. 
The most promising and new technique for promoting dissolution is the 
formation of liquisolid tablets among the various novel techniques. 
Liquisolid compacts promote dissolution rate of water-insoluble drugs to 
a greater extent and also enhances the drug flow property [5]. 
The liquisolid technique is a novel and most promising technique for 
improving the dissolution rate of poorly water-soluble drugs. With 
the liquisolid technology, a liquid may be transformed into a free-
flowing, readily compressible and apparently dry powder by simple 
physical blending with selected excipients named the carrier and 
coating material [5, 6]. 
Furosemide is 5-(Aminosulfonyl)-4–chloro–2-[(2–furanyl methyl) 
amino] benzoic acid (fig. 1), the empirical formula is C12H11ClN2O5S 
corresponds to the molecular weight of 330.77. Furosemide is a 
white to slightly yellow, odourless, almost tasteless crystalline 
powder, slightly soluble in water, chloroform and ether, soluble in 
acetone, methanol, dimethyl formamide and in solutions of alkali 
hydroxides. Its melting point is 206 °C [7]. 
 
 
Fig. 1: Chemical structure of furosemide [8] 
 
Furosemide is a loop diuretic act primarily by inhibiting chloride and 
sodium reabsorption over the entire length of the thick ascending limb of 
the loop of Henle, it is widely used for the symptomatic treatment of 
heart failure and fluid retention in chronic kidney disease [9]. 
The present research work was aimed to prepare furosemide 
liquisolid compact and to enhance the solubility and dissolution rate 
of furosemide by liquisolid technique. 
MATERIALS AND METHODS 
The following gift samples were received: furosemide from (Awa 
medica, Erbil), microcrystalline cellulose PH 102 (FMC, USA), Aerosil 
200 and crospovidone (Wuhan Senwayer Century chemical Co., Ltd), 
PEG 400, and sodium starch glycolate (were obtained from SD Fine 
Chem Ltd., Mumbai, India), magnesium stearate (Robert E. M. TILG, 
Germany). All reagents used were of analytical grade. 
Methods 
Solubility studies 
Solubility studies of furosemide were carried out in water, 
phosphate buffer pH 5.8 and polyethene glycol (PEG 400). Saturated 
solutions were prepared by adding an excess drug to the vehicle and 
shaking in a water bath with a shaker for 48h at 25±0.5 °C under 
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constant vibration. After this period the solutions were filtered, 
diluted and analyzed by UV spectrophotometer (Cary, Australia) at 
277 nm. Three determinations were carried out for each sample to 
calculate the solubility of furosemide. 
Application of the mathematical model for designing the 
liquisolid systems 
The formulation design of liquisolid systems was done in accordance 
with new mathematical model described by Spireas et al. 
In this study, PEG 400, microcrystalline cellulose (Avicel® PH 102-
MCC), and Aerosil® 200 were used as a liquid vehicle, carrier and 
coating materials respectively. The concentration of the drug in 
liquid vehicle was varied and the carrier: coating ratio was kept 
constant in all formulations (R=25:1). 
Depending on the excipient ratio (R) of the powder substrate an 
acceptably flowing and compressible liquisolid system can be 
obtained only if a maximum liquid load on the carrier material is not 
exceeded. This liquid/carrier ratio is termed “liquid load factor Lf 
[w/w] and is defined as the weight ratio of the liquid formulation 
(W) and the carrier material (Q) in the system:  
Lf = W/Q ------ (1) 
R represents the ratio between the weights of the carrier (Q) and the 
coating (q) material present in the formulation:  
R =Q/q ------ (2) 
The liquid load factor that ensures acceptable flowability (Lf) can be 
determined by:  
Lf =Φ+φ. (1/R) ----- (3) 
Where √ and φ are the Ф-values of the carrier and coating material, 
respectively [10].  
In order to calculate the required ingredient quantities, the flowable 
liquid retention potentials (Φ-values) of powder excipients were 
utilized. In polyethylene glycol 400, the Φ-value of Avicel PH 102 
was found to be 0.005 and the φ-value for Aerosil 200 was 3.26 [11]. 
So, by knowing both Lf and W, the appropriate quantities of carrier (Q) 
and coating (q) powder materials required to convert a given amount of 
liquid medication (W) into an acceptably flowing and compressible 
liquisolid system could be calculated from equation (1) and (2). 
Preparation of co-processed superdisintegrant  
The co-processed superdisintegrants were prepared by solvent 
evaporation method. A blend of crospovidone and sodium starch 
glycolate (in the ratio 1:1) was added to 10 ml of ethanol. The 
contents of the beaker (250 ml capacity) were mixed thoroughly and 
stirring was continued until most of the ethanol evaporated. The wet 
coherent mass was granulated through #44 mesh sieve.  
The wet granules were dried in a hot air oven at 60 C˚ for 20 min. 
The dried granules were sifted through #44 mesh sieve and stored 
in an airtight container until further use [12, 13]. 
The co-processed superdisintegrants at a ratio (1:1) was used in the 
preparation of liquisolid compacts to study the effect of co-
processed superdisintegrants on the disintegration and dissolution 
rate of furosemide liquisolid compacts. 
Preparation of furosemide liquisolid compact 
Four liquisolid tablets denoted (F1 to F4) containing 40 mg of 
furosemid were prepared by dispersing in the non-volatile vehicle 
(PEG 400). Then a bindery mixture of the carrier (Avicel PH 102) 
and coating material (Aerosil 200) was prepared at a ratio of 25: 1, 
by continuous mixing for a period of 10 min in a mortar. The amount 
of carrier and coating materials are enough to maintain acceptable 
flow and compression properties. R 25 was used in all formulations 
since it gave the optimal flow property. 
Finally, a 5 %w/w of co-processed superdisintegrant (crospovidone and 
sodium starch glycolate at ratio 1:1) was added and mixed for 10 min 
then 1 % w/w of magnesium stearate as a lubricant was added into the 
mixture and mixed for 2 min. The final mixture was compacted using a 
single punch-tablet machine (Korsch EKO, Germany) [14]. The 
composition of liquisolid tablets is shown in table 1. 
Preparation of direct conventional tablet of furosemide 
Furosemide conventional tablets were produced by mixing the drug 
with Avicel PH 102 and aerocil 200 (ratio of microcrystalline 
cellulose: aerocil was 25:1) for a period of 10 min in a mortar 
without the addition of the vehicle. The mixture then was mixed 
with (5%) of co-processed super-disintegrant (1:1) for 10 min, and 
then (1%) of magnesium stearate was mixed for 2 min. The mixture 
was compressed using a single punch tablet machine (Korsch, 
Germany). This formulation was denoted as DCT [15]. 
 






























F1 40 25 0.1354 60 40 738.6 30 43 9.1 920.7 
F2 50 25 0.1354 40 40 591 24 35 7.3 737.3 
F3 60 25 0.1354 27 40 495 20 29 6.11 617.11 
F4 70 25 0.1354 17 40 421 17 25 5.2 525.2 
Excipient ratio, R=Q/q, Q= Weight of carrier, q= Weight of coating material, Liquid load factor, Lf= W/Q, W= Weight of liquid medication, Q= Weight 
of carrier  
 
Pre-compression studies 
Characterization of powder mixture  
Angle of repose  
The frictional force of a loose powder can be measured by the angle 
of repose (θ). The fixed funnel method was employed to measure the 
angle of repose. A funnel was secured with its tip at a given height 
(h), above a Petri dish is placed on a flat horizontal surface. The 
blend carefully pored through the funnel until the apex of the conical 
pile just touches the tip of the funnel. The radius (r) of the base of 
the conical pile was measured. 
The angle of repose (θ) was calculated using the following formula:  
Tan θ = h/r 
Where; θ = angle of repose, h = height of the cone in cm, r = radius of 
the cone base in cm [16]. 
Bulk and tapped density  
An accurately weighed quantity of the liquisolid powder (w) was 
carefully poured into the graduated cylinder and the volume (vo) 
was measured. The graduated measuring cylinder was tapped for 
1000 times and after that, the volume (vf) was measured. The bulk 
density and tapped density were calculated using the formulas 
below:  












Where w is the weight of powder, vo is the initial volume and vf is 
the final volume. 
From the results of bulk density and tapped density, carr’s index was 
calculated [17] 
Carr’s index = 
Tapped densityBulk density
Tapped density  x100 
Post-compression studies 
Hardness  
The hardness of the tablet was determined using Monsanto 
hardness tester. Three tablets were randomly selected from each 
formulation and hardness of the same was determined. The average 
value was calculated [14]. 
Friability testing  
Friability of the tablets was determined by using Roche friabilator. A 
number of tablets (equal to 6.5g or more in weight) were placed in 
the friabilator and rotated at 25rpm for a period of 4 min. The 





Where W1= initial weight of tablets, W2= weight of the tablets after 
testing [15, 18]. 
Content uniformity 
The drug content of the tablets was measured according to united 
state pharmacopoeia USP. Ten tablets were selected randomly from 
each formula; each tablet was crushed in a mortar and transferred it 
into a 100 ml volumetric flask and sonicated for 10 min. Then 
volume made up to 100 ml with phosphate buffer pH 5.8. Then 1 ml 
of resultant solution diluted to 100 ml with buffer solution pH 5.8. 
Measure the absorbance of above solution using UV spectro-
photometer at 277 nm [19]. 
Weight variation 
Twenty tablets were weighed individually and then all together. 
Average weight was calculated from the total weight of all tablets. 
The individual weights were compared with the average weight. The 
percentage difference in the weight variation should be within the 
permissible limits as specified in USP, not more than two tablets 
should differ in their average weight by more than percentages 
stated in USP. No tablet must differ by more than double the relevant 
percentage [20]. 
Disintegration test 
The disintegration time was determined in water maintained at 
37±2˚C. The disintegration apparatus with a basket rack assembly 
containing six open-ended tubes and 10-mesh screen on the 
bottom was used. A tablet was placed in each tube of the basket 
and the time for complete disintegration of the six tablets was 
recorded [21-23]. 
In vitro dissolution test 
The dissolution rates of all formulations were measured by using 
tablet dissolution apparatus USP Type II. Dissolution studies were 
carried out using 900 ml of phosphate buffer pH 5.8, at 50 rpm and 
at a temperature of 37±0.5 ˚C. 10 ml of the medium was withdrawn 
at a suitable time interval, filtered and diluted with phosphate buffer 
pH 5.8. Sink conditions were maintained throughout the study. The 
samples were then analyzed at 277 nm by UV/visible 
spectrophotometer. The study was carried out in triplicate [15,24]. 
Dissolution data evaluation 
For the comparison of dissolution data for each formulation, 
percentages of drug dissolved at 10 min (Q10 min), mean 
dissolution time (MDT) and percentage of dissolution efficiency 
(%DE) at the end of 60 min were calculated using DDsolver software 
in order to select the optimized formula. 
The model-independent approach includes the difference factor (f1) and 
the similarity factor (f2) was used to compare between the dissolution 
profile of optimized formula and the DCT. The f1 factor measures the 
percentage error between two curves over all time points:  
f1 = ∑ = 1|Rt − Tt|nt ∑ = 1Rtnt × 100 
Where n is the number of time points and Rt and Tt are the 
percentages of the reference and test product dissolved, 
respectively, at each time point. The percentage error is zero when 
the test and drug reference profiles are identical and increases 
proportionally with the dissimilarity between the two dissolution 
profiles [25].  
The similarity factor (f2) is a logarithmic transformation of the sum-
squared error of differences of drug percentage dissolved between 
the test and the reference products over all time points:  







)( ) − 0.5
 
× 100 
Where n is the number of time points at which % dissolved was 
determined, Rt is the % dissolved of one formulation at a given time 
point, and Tt is the % dissolved of the formulation to be compared at 
the same time point [26]. 
Differential scanning calorimetry (DSC) 
Samples (3-5 mg) were placed in an aluminum pan and heated in 
the DSC 60-plus (Shimadzu, Japan) at a constant rate of 10 
°C/min, in an atmosphere of nitrogen over a temperature range 
of 25-300 °C. The DSC studies were performed on the pure drug, 
a physical mixture of the optimized liquisolid system, and on the 
liquisolid tablet [27]. 
Fourier-transform infrared spectroscopy (FTIR) 
It was performed using the infrared spectrophotometer (Lambda 
7600, Australia). Samples of 2-3 mg were mixed with about 100 mg 
of dry potassium bromide powder and compressed into transparent 
discs then scanned over a wave range of 4000-400 cm-1in FTIR 
instrument. FTIR spectra were performed on the pure drug, sodium 
starch glycolate, crospovidone, co-processed superdisintegrant at a 
ratio (1:1), a physical mixture of optimized liquisolid system and on 
the liquisolid tablet [28]. 
X-ray powder diffraction (XRPD) 
X-ray diffractograms of pure furosemide, physical mixture of 
liqisolid and liquisolid tablet were obtained using analytical XRD 
instrument. The scanning range was from 5 to 60˚ at 2 theta scale 
and 5 degree/min. The voltage and strength of the electric current 
were 40 KV and 30 mA, respectively [29].  
Statistical analysis  
All the results were expressed as the mean value±standard deviation 
(SD). T-test was used to test for significance, at a 5% significance 
level. Statistical difference dealing (P<0.05) was considered 
significant [30]. 
RESULTS AND DISCUSSION 
Saturation solubility studies 
The solubility of furosemide in different media is presented in table 
2. Drug solubility in a non-volatile vehicle is the most important 
aspect in liquisolid systems. The solubility of the drug contributes to 
molecular dispersion in a non-volatile solvent which will improve 
the dissolution rate. 
The solubility of furosemide in macrogol 400 (98.69 mg/ml) was 
approximately 10000 times higher than in water (0.006 mg/ml). 
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Table 2: Solubility of furosemide in various media 
Medium Solubility (mg/ml)±SD* 
Distilled water 0.006±0.9 
Phosphate buffer pH 5.8 0.72±2 
PEG 400 98.69±1.4 
* Results were expressed in mean±SD (n=3), SD standard deviation 
 
Flowable liquid retention potential (Ф value) and liquid load 
factor (Lf)  
Ф value of carrier and coating materials in polyethene glycol 400 
were cited in the literature and found to be 0.005 and 3.26 
respectively. According to mathematical model proposed by Spireas 
et al. equation for Avicel PH-102 and Aerosil 200 in polyethene 
glycol 400 was calculated by using R-value = 25 as   = .+. (/) 
So, L = 0.1354 
Pre-compression evaluation 
Angle of repose 
Angle of repose provides a qualitative and quantitative assessment 
of internal cohesive and frictional force under low level of external 
load applied during mixing and tableting. Values less than 35 
indicate good flow whereas greater than 35 indicates poor flow. 
The results of the angle of repose and carr’s index were given in the 
table 3. The results showed that angle of repose was ranged from 
30.8˚ to 34.8˚. It was found that formula of highest drug 
concentration in PEG 400 has better flowability than another 
formula due to fewer amounts of vehicle presents on the surface of 
the carriers in liquisolid formulations. 
We could not increase the R in order to enhance the flowability 
because the tablet weight will increase above 1 gm and difficult to be 
compressed by the available tablet machine. 
Hardness test 
Hardness of the prepared tablets of all formulations is within the 
acceptable limit. Hardness of tablets prepared by direct compression 
was found to be from 3 to 10 kg/cm2 as shown in table 4. Generally, 
the ideal tablet hardness should be produced without applying 
excessive compression force where rapid tablet disintegration and 
drug dissolution are maintained at the same time [31]. 
  
Table 3: Flow properties of furosemide liquisolid powder and DCT 
Formula Angle of repose* Type of flow Carr’s index* Type of flow 
F1 34.8±0.85 good 14.5±2.5 good 
F2 32±2.8 good 18.1±2.5 Fair 
F3 31.9±1.5 good 21±2 passable 
F4 30.8±3 good 21.4±4 passable 
DCT 33.6±0.5 good 19±1 fair 
*Results were expressed in mean±SD (n=3), SD standard deviation, DCT: direct conventional tablet 
 
Friability test 
All furosemide tablets had acceptable friability as none of the tested 
formulas exceeded 1% loss in tablet weight as shown in table 4; also, 
no tablet was cracked, split or broken in either formulation. Since all 
the prepared formulas met the standard friability criteria, they are 
expected to show acceptable durability and withstand abrasion. 
Formulations containing a higher level of nonvolatile solvent were 
able to reflect greater interparticulate bonding between particles, 
resulting in low friability percent [32]. 
Disintegration time 
The disintegration time for the prepared furosemide liquisolid 
tablets was shown in table 4. It was found that the mean of the 
disintegration times for all investigated tablets was less than 1 min, 
due to the effect of co-processed super disintegrant. Co-processing 
of excipients could lead to the formation of excipients with superior 
properties compared with a simple physical mixture of their 
components or with individual components [33].  
Co-processed superdisintegrant accelerated the disintegration of 
tablets by virtue of its ability to absorb a large amount of water when 
exposed to an aqueous environment [34]. The results reveal that co-
processing resulted in the formation of quickly disintegrating tablets. 
The probable reason for the faster disintegration could be the 
development of a higher disintegration force, this force generated by 
disintegrant particles is more critical than the actual swelling because 
this force is responsible for the breaking up of the tablet [35]. 
Also due to high Avicel pH 102 content, where Avicel PH 102 
functions as a swellable disintegrant, in combination with 
hydrophilic solvent PEG 400, which improves wetting properties of 
the obtained liquisolid tablets and hence facilitate the volume 
expansion of superdisintegrant [36]. 
Weight variation 
Tablets of each formula were subjected to weight variation test, the 
difference in weight and percent deviation was calculated for each 
tablet. The results of the test showed that the tablet weights were 
within pharmacopoeia limit as shown in table 4. 
 











F1 3±1 0.12 30±0.9 96.6±2 932.9±4.94 
F2 3.7±0.577 0.14 28±1.032 97±1 743.15±4 
F3 3.5±0.5 0.28 24±0.81 99.6±0.8 621.55±2.9 
F4 6.8±0.29 0.29 29±1.2 97±0.86 511.15±3 
DCT 10±2 0.5 31±0.2 99±0.9 732.5±3 
* Results were expressed in mean±SD (n=3), SD standard deviation, DCT: direct conventional tablet, s: second 
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Drug content  
The drug content for tablets of all the formulations ranges from 
96.6-99.6% (table 4). The results indicate that the contents for 
tablets of all the formulations were uniform and contains a 
therapeutic dose of the active ingredients. 
In vitro dissolution test 
The results of in vitro drug released are plotted against time in 
phosphate buffer solution pH 5.8 to obtain the dissolution profiles as 
shown in fig. 2 and 3. MDT, Q10 min, and % DE of each liquisolid 
formula and DCT were calculated and reported in table 5. 
 
Table 5: Model-independent parameters of liquisolid compacts and DCT 
Formula Q10 min MDT (min) %DE 
F1 74% 7.85 87 
F2 90% 5.9 90 
F3 67% 9.9 84 
F4 78% 9.4 84 
DCT 65% 13.8 77 
Q10 min: percentages of drug dissolved at 10 min, MDT: mean dissolution time, DE: dissolution efficiency, DCT: direct conventional tablet. Values 
was represented as mean±SD 
 
The percentage of furosemide released from liquisolid compacts 
containing PEG 400 (from F1 to F4) was found to vary from 
67±0.32% to 90±0.78% in first 10 min, while 65%±0.3 of drug 
release from DCT. This indicates fast release of the drug is observed 
from above liquisolid tablets. 
From the calculations of %DE and MDT, F2 (at drug concentration 
50% w/w in liquid medication) formulation showed better 
improvement in dissolution and it is considered as optimized 
formulation. The reduction in mean dissolution time (MDT) values 
indicates the faster release of drug from formulation F2 compared to 
other formulations. 
The release of furosemide from F2 was also compared with DCT 
(fig. 3) prepared in a similar manner without nonvolatile liquid 
to study the effect of nonvolatile solvents on drug dissolution. 
The release from DCT was 78 % in 30 min compared to complete 
drug release from the liquisolid formulation. The difference in 
dissolution was found to be significant (p<0.05) using student’s t-
test analysis. This clearly indicates the improvement in the 
dissolution of furosemide was due to the presence of the drug in 
nonvolatile solvent in the liquisolid formulation. 
The increased dissolution from liquisolid formulation could be due 
to the presence of the drug insoluble state in the formulation, which 
contributes to the increased wetting properties, thereby enhancing 
the dissolution rate. Similarly, as the formulation disintegrates in 
dissolution media, the drug will be presented in a state of molecular 
dispersion. This will increase the effective surface area of the 
particles available for dissolution [15]. 
Concerning the drug concentration in the liquid vehicle, as the drug 
concentration decreased, the portion solubilized and molecularly 
dispersed in the liquid vehicle increased thus leading to better 
dissolution [37-39].  
In addition, the more vehicles available, the more even the 
distribution of the vehicle over the remaining undissolved drug 
particles that would help in better wetting of the drug through the 
dissolution stage [40]. 
A pairwise procedure such as dissimilarity (f1) and similarity (f2) 
factors provides a simple way to compare dissolution data. Food and 
drug administration (FDA) guidance proposes that f1 value between 
0 and 15 and f2 value between 50-100 indicate equivalence in 
dissolution profiles [25,26]. In comparison between the dissolution 
of F2 and the DCT, the results of f1 and f2 were 16.22 and 36.18 
respectively gave an indication that the two dissolution profiles are 
equivalent. 
Differential scanning calorimetry (DSC) 
The differential scanning calorimetry (DSC) thermograms of 
furosemide, a physical mixture of F2 liquisolid and F2 liquisolid 
tablet are illustrated in fig. 4, 5 and 6 respectively. Furosemide 
exhibits two characteristics, sharp endothermic peak at 218.16˚C 
and exothermic peak at 222.32˚C, which are associated with the 
decomposition and melting points of the drug and indicate the 
crystalline nature of the drug [41, 42]. The physical mixture of 
liquisolid and liquisolid tablet showed the partial disappearance of 
the characteristic peak of furosemide, supporting the probable 
phenomena of getting molecularly dispersed into the liquisolid 
matrix system, which suggests conversion of the drug into an 
amorphous form. This supports the in vitro release studies data of 
improved drug release and indicating no interaction between 
furosemide and excipients [43]. 
 
 
Fig. 2: Dissolution profile of furosemide from liquisolid tablets 
(values represent mean±SD, n=3) 
 
 
Fig.3: Dissolution profile of furosemide from F2 and DCT 
(values represent mean±SD, n=3), DCT: direct conventional 
tablet 
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Fig. 6: DSC thermogram of F2 liquisolid tablet 
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Fourier-transform infrared spectroscopy (FTIR) 
FTIR was performed to detect any sign of interaction which would 
be reflected by a change in the position or disappearance of any 
characteristic stretching vibration of furosemide. Fig. 7 showed the 
characteristic peaks of furosemide of N-H stretching at 3399 cm-1, N-
H stretching in sulfonamide at 3349 and 3284 cm-1. The C=O 
stretching, the vibration was at 1671 cm-1, S=O stretching, vibration 
at 1141 cm-1 and 1322 cm-1, most important stretching vibration was 
OH stretching at 3122 cm-1, NH bending at 1563-1590 cm-1 [44]. 
As shown in fig. 8 and 9 respectively, The FTIR spectra of physical 
mixture and tablet of liquisolid formulations F2 showed 
characteristic distinct peaks mainly for Avicel PH 102, and furo-
semide. Thus, there is no undesired interaction between the drug 
and excipients. It can be noticed a reduction in intensity of the 
characteristic absorption bands of the drug in liquisolid 
formulations which might be attributed to the hydrogen bonding 
interaction of the amino and carboxyl group of furosemide with the 
hydroxyl group of the liquid vehicles PEG 400 [45]. 
FTIR spectra of crospovidone and sodium starch glycolate were 
shown in fig. 10 and 11 respectively, FTIR of co-processed 
superdisintegrants showed retention of all the major peaks of 
individual polymer (sodium starch glycolate and crospovidone) 
which indicates the absence of chemical interaction between 
polymers during processing as in fig. 12. 
 
 
Fig. 7: FTIR spectrum of furosemide 
 
 
Fig. 8: FTIR spectrum of physical mixture of F2 liquisolid 
 
 
Fig. 9: FTIR spectrum of F2 liquisolid tablet 
 
 
Fig. 10: FTIR spectrum of crospovidone 
 
 
Fig. 11: FTIR spectrum of sodium starch glycolate 
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Fig. 12: FTIR spectrum of co-processed superdisintegrants 
 
X-ray powder diffraction (XRPD) 
Fig. 13, 14 and 15 show XRPD of pure furosemide, a physical mixture 
of F2 liquisolid compact and F2 liquisolid tablet. X-ray diffraction 
pattern in fig. 13 demonstrated that pure furosemide was clearly in 
crystalline state as it showed sharp distinct peaks at 2θ diffraction 
angles of 6˚, 22˚ and 24˚ with high intensity. XRPD pattern of a 
physical mixture of F2 liquisolid compact and liquisolid tablet in fig. 
14 and 15 respectively showed the absence of sharp peaks and 
appeared as a diffused pattern peaks at 2θ angles in the 15˚, 16˚, 20˚ 
and 22˚ with low intensity. 
The disappearance of sharp peaks is evident that crystalline pure 
drug is converted into amorphous state due to its molecular 
solubilization of the drug in the non-volatile solvent that was 
absorbed into and adsorbed onto the carrier and coating material, 
which proves the enhancement of solubility by this technique. 
Results confirmed the formation of drug solution into a liquisolid 
system which again supports and confirms the DSC results [46]. 
 
 
Fig. 13: XRD of furosemide 
 
 
Fig. 14: XRD of physical mixture of F2 liquisolid compact 
 
 
Fig. 15: XRD of F2 liquisolid tablet 
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The liquisolid technique succeeded to improve the dissolution rate of 
the practically insoluble drug such as furosemide. Among the liquisolid 
tablets tested, F2 prepared using PEG 400 as a non-volatile liquid 
vehicle, at the R-value of 25 and containing 50% drug concentration, 
possessed reasonable flow, rapid dissolution time and the highest 
dissolution rate compared to other formulations. The results of 
investigations demonstrate that 40 mg furosemide tablets with 
acceptable size, mass, fast and entire drug dissolution could be 
prepared by selection of suitable drug concentration in a liquid vehicle. 
ACKNOWLEDGEMENT 
We are thankful to Dr. Nawal Ayash for providing gift sample of 
furosemide, Avicel PH 102 and grateful to MSc. Mohammed Iqdam 
Mohammed for his invaluable support and providing necessary 
facilities to carry out the research work. 
CONFLICT OF INTERESTS 
Declared none 
REFERENCES 
1. Altememy D, Altememy JJ. Formulation and evaluation of 
meloxicam liquisolid compact. Int J Pharm Pharm Sci 
2014;6:453-63. 
2. Vemula S, Radhika K. Liquisolid compact technique for 
improvement of the dissolution rate of flurbiprofen: formulation 
and evaluation. J Drug Res Dev 2015;1:2470-1009, 102. 
3. Prajila A, Vipin K, Chandran S, Premaletha K, Augusthy A. 
Formulation and evaluation of deflazacort liquisolid tablets. Int 
J Res Pharm Sci 2016;6:19-25. 
4. Lahmo P, Singh SK, Garg V, Maharshi P, Yadav AK, Gulati M, et 
al. Influence of formulation parameters on dissolution rate 
enhancement of piroxicam using the liquisolid technique. Asian 
J Pharm Clin Res 2016;9:1-6. 
5. Kumar Nagabandi V, Ramarao T, Jayaveera K. Liquisolid 
compacts: a novel approach to enhance bioavailability of 
poorly soluble drugs. Int J Pharm Biol Sci 2011;1:89-102. 
6. Satyajit Panda, R Varaprasad, K Priyanka, Ranjit P Swain. 
Liquisolid technique: a novel approach for dosage form design. 
Int J Appl Pharm 2017;9:8-14. 
7. Mangal G, Dhobale S. Development of UV spectrophotometric 
methods and validation for estimation of furosemide in bulk 
and tablet dosage form by absorbance maxima and area under 
the curve method. Int J Adv Pharma 2016;5:160-70. 
8. Acid F, Acid A, Acefyllinate A, Camphorate A, Persulfate A, Alfa 
A, et al. Martindale: the complete drug reference. 
Pharmaceutical Press; 2014. 
9. Smith H. Diuretics: a review for the pharmacist: a review. SA 
Pharm J 2014;81:18-21. 
10. El-Hammadi M, Awad N. Investigating the use of liquisolid 
compacts technique to minimize the influence of pH variations 
on loratadine release. AAPS PharmSciTech 2012;13:53-8. 
11. Spireas S. Liquisolid systems and methods of preparing same. 
Google Patents; 2002. 
12. Kaur M, Bala R, Arora S. Formulation and evaluation of 
liquisolid compacts of amlodipine besylate. Int Res J Pharm 
2013;4:156-60. 
13. Gohel MC, Parikh RK, Brahmbhatt BK, Shah AR. Preparation 
and assessment of novel co-processed superdisintegrant 
consisting of crospovidone and sodium starch glycolate: a 
technical note. AAPS PharmSciTech 2007;8:E63-E9. 
14. Bhairav BA, Jadhav MS, Saudagar R. Formulation and 
evaluation of liquisolid tablet of felodipine. World J Pharm 
Pharm Sci 2016;5:1670-85. 
15. Saeedi M, Akbari J, Morteza-Semnani K, Enayati-Fard R, Sar-
Reshteh-dar S, Soleymani A. Enhancement of dissolution rate of 
indomethacin: using liquisolid compacts. Iran J Pharm Res 
2011;10:25. 
16. Mohammed Asif Hussain Mg, T Rama Rao, Maimuna Anjum. 
Preparation and evaluation of nilvadipine liquisolid compacts. 
Int J Pharm Pharm Sci 2014;6:1-8. 
17. Messa R, Ampati S. Comparative studies for enhancement of the 
dissolution profile of pitavastatin. Int J Med Nano 2016;3:311-5. 
18. Mahendran Baskaran KBT, Gowthamarajan Kuppusamy, Veera, 
Kollipara VSRKa R. Formulation development of atorvastatin 
calcium tablets by gel liquisolid compact technique for 
improving solid-state stability and dissolution profile. J Drug 
Res Dev 2016;2:1-7. 
19. Arun Raj, R AsAKaJ H. Formulation and evaluation of liquisolid 
tablets of nifedipine. RGUHS J Pharm Sci 2013;3:43-50. 
20. Kapoor D, Patel M, Vyas RB, Lad C. Formulation development, 
optimization and in vitro characterization of liquisolid 
compacts of an oxicam derivative. J Drug Delivery Ther 
2016;6:64-70. 
21. Abbas Aaa, Rasool Aaa, Rajab Na. Preparation and comparative 
evaluation of liquisolid compact and solid dispersion of 
candesartan cilexetil. Int J Pharm Pharm Sci 2014;6:257-66. 
22. Trustees USPCBo, Convention USP, Revision USPCCo, Board NF. 
The united states pharmacopoeia: National formulary. 
Supplement. United States; 2006. 
23. Deshmukh P. Dissolution enhancement of rosuvastatin calcium 
by liquisolid compact technique. J Pharm 2013:1-9. 
http://dx.doi.org/10.1155/2013/315902 
24. Sayyad FJ, Tulsankar SL, Kolap UB. Design and development of 
liquisolid compact of candesartan cilexetil to enhance 
dissolution. J Pharm Res 2013;7:381-8. 
25. Eedara BB, Kankane M, Jukanti R, Nagabandi VK, Bandari S. 
Enhanced solubility and permeability of exemestane solid 
dispersion powders for improved oral delivery. J Pharm Inves 
2013;43:229-42. 
26. Adibkia K, Shokri J, Barzegar-Jalali M, Solduzian M, Javadzadeh 
Y. Effect of solvent type on retardation properties of diltiazem 
HCl form liquisolid tablets. Colloids Surf B 2014;113:10-4. 
27. Abd-El Bary A, Louis D, Sayed S. Liquisolid tablet formulation as 
a tool to improve the dissolution of olmesartan medoxomil. 
Inventi Rapid: NDDS 2014;3:1-8. 
28. Rajesh Asija SB, Sangeeta Asija, Alpesh Yadav, Isha Shah. 
Enhancement of solubility and dissolution of lercanidipine by 
liquisolid technique. J Chem Pharma Res 2014;6:2680-6. 
29. Sanka K, Poienti S, Mohd AB, Diwan PV. Improved oral delivery 
of clonazepam through liquisolid powder compact 
formulations: in vitro and ex-vivo characterization. Powder 
Technol 2014;256:336-44. 
30. Elkhodairy KA, Hassan MA, Afifi SA. Formulation and 
optimization of orodispersible tablets of flutamide. Saudi 
Pharm J 2014;22:53-61. 
31. Singh Y. Martin’s physical pharmacy and pharmaceutical 
sciences: department of pharmaceutics ernest mario school of 
pharmacy rutgers, the State University of New Jersey; 2006. 
32. Javadzadeh, Yousef. Effect of some commercial grades of 
microcrystalline cellulose on flowability, compressibility, and 
dissolution profile of piroxicam liquisolid compacts. Drug Dev 
Ind Pharm 2009;35:243-51. 
33. Karia I, Parmar RB. Formulation and evaluation of fast 
dissolving tablets of olmesartan medoxomil by using co-
processed excipients techique. World J Pharm Pharm Sci 
2015;4:1356-73. 
34. Patil BS, Rao NR. Formulation and evaluation of fast dissolving 
granisetron hydrochloride tablets: effect of the functionality of 
superdisintegrants. Int J Adv Pharm Sci 2011;2:33-9. 
35. Gohel MC, Parikh RK, Brahmbhatt BK, Shah AR. Improving the 
tablet characteristics and dissolution profile of ibuprofen by 
using a novel co-processed superdisintegrant: a technical note. 
AAPS PharmSciTech 2007;8:E94-E9. 
36. Vranikova B, Gajdziok J, Dolezel P. The effect of superdisintegrants 
on the properties and dissolution profiles of liquisolid tablets 
containing rosuvastatin. Pharm Dev Technol 2017;22:138-47. 
37. Spireas S, Sadu S. Enhancement of prednisolone dissolution 
properties using liquisolid compacts. Int J Pharm 1998; 
166:177-88. 
38. Javadzadeh Y, Siahi-Shadbad M, Barzegar-Jalali M, Nokhodchi A. 
Enhancement of dissolution rate of piroxicam using liquisolid 
compacts. Il Farmaco 2005;60:361-5. 
39. Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali 
M. The effect of type and concentration of vehicles on the 
dissolution rate of a poorly soluble drug (indomethacin) from 
liquisolid compacts. J Pharm Pharm Sci 2005;8:18-25. 
Jassim 
Int J App Pharm, Vol 9, Issue 6, 2017, 39-48 
 
48 
40. Prajapati ST, Bulchandani HH, Patel DM, Dumaniya SK, Patel 
CN. Formulation and evaluation of liquisolid compacts for 
olmesartan medoxomil. J Drug Delivery 2013;1-9. http:// 
dx.doi.org/ 10.1155/2013/870579. 
41. Chaulang G, Patil K, Ghodke D, Khan S, Yeole P. Preparation and 
characterization of solid dispersion tablet of furosemide with 
crospovidone. Res J Pharm Tech 2008;1:386-9. 
42. Aceves JM, Cruz R, Hernandez E. Preparation and 
characterization of Furosemide-Eudragit controlled release 
systems. Int J Pharm 2000;195:45-53. 
43. Parmar K, Patel J, Sheth N. Fabrication and characterization of 
liquisolid compacts of Embelin for dissolution enhancement. J 
Pharm Inves 2014;44:391-8. 
44. Chatap VK, Patil PL, Patil SD. In vitro, ex-vivo 
characterization of furosemide bounded pharmacosomes 
for improvement of solubility and permeability. Adv Pharm 
Pharm 2014;2:67-76. 
45. Dias RJ, Mali KK, Ghorpade VS, Daulatrao V, Havaldar VRM. 
Formulation and evaluation of carbamazepine liquisolid 
compacts using novel carriers. Indian J Pharm Edu Res 
2017;51:69-78. 
46. Parmar K, Patel J, Sheth N. Formulation and development of 
embelin liquisolid systems using quality by design approach. J 
Pharm Inves 2016;46:547-56. 
 
